Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Fineline Cube Jan 19, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug Medical Device

Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu

Fineline Cube Apr 11, 2024

Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...

Company Drug

Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults

Fineline Cube Apr 11, 2024

Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...

Company

Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply

Fineline Cube Apr 11, 2024

Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals...

Company Deals

Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation

Fineline Cube Apr 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...

Company Deals

Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China

Fineline Cube Apr 11, 2024

Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors

Fineline Cube Apr 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...

Company

Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...

Company Deals

Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology

Fineline Cube Apr 10, 2024

Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...

Company Deals

Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions

Fineline Cube Apr 10, 2024

Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology...

Company Drug

Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma

Fineline Cube Apr 10, 2024

Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...

Company Drug

Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...

Company Drug

Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer

Fineline Cube Apr 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...

Company Deals

Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development

Fineline Cube Apr 10, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has...

Company Deals

Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline

Fineline Cube Apr 10, 2024

Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the...

Company Deals

Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China

Fineline Cube Apr 10, 2024

US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for HRS-4642 Clinical Trial in KRAS G12D Mutated Tumors

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study

Fineline Cube Apr 10, 2024

Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...

Company Drug

Gan & Lee Pharmaceuticals Commences Clinical Trial for Innovative GLP-1 Agonist GZR18

Fineline Cube Apr 9, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement...

Company

BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle

Fineline Cube Apr 9, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has announced the operational...

Posts pagination

1 … 321 322 323 … 611

Recent updates

  • Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise
  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.